$SRPT

AI Analysis

Generated on May 11, 2026

AI Score
55/ 100
Hold$SRPT

Sarepta Therapeutics

$SRPTNASDAQHealthcareMid-Cap

Sarepta develops RNA-based therapeutics for rare neuromuscular diseases including Duchenne muscular dystrophy.

Market Cap
$12.0B
Revenue (TTM)
$1.5B
+35.0%
Net Income (TTM)
-$0.5B
N/A
EPS (TTM)
-$5.50
P/E Ratio
N/A
Dividend Yield
0.0%
52-Week Range
$85-$170
Beta
1.12
Dimension Scores
Fundamental
45
Technical
52
Sentiment
62
Risk / Reward
48
Momentum
65
FundTechSentRiskMome
Financial Health
Profitability
50weak
Growth
68moderate
Liquidity
56strong
Solvency
47moderate
Efficiency
43moderate

Valuation, technical analysis, investment thesis, risk assessment and more for $SRPT

Free · No credit card required

Disclaimer: AI-generated analysis for educational purposes only. Not financial advice. Always consult a qualified financial advisor.

Explore more

Analyze any stock with AI

Get a structured equity research report covering fundamentals, technicals, sentiment, risk, and investment thesis — in about 60 seconds.